Executives from the largest companies in the industry discuss the increasing prevalence of biologics and the future focus for therapeutics at Pharma Integrates.
After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
GE to set up its FlexFactory platform for antibody manufacturing at Akeso’s facility in Guangzhou, aiming to optimize the latter’s biologics production.
Solid Biosciences announces that its gene therapy for DMD has been placed under clinical hold again, after a patient experienced a serious adverse event.
NIH and the Gates Foundation have set themselves the goal of bringing curative gene therapies to clinical trials in the US and Africa in the next seven to 10 years.
During this year’s Festival of Biologics conference, one track saw a focus on biosimilars that brought together experts from across the industry to map the future for such treatments in the EU and US.
Ichnos will launch with a portfolio of five clinical stage assets, a proprietary platform, as well as a biologics manufacturing facility and 350 employees.
Sanofi opens its Massachusetts, US-based facility that will use digital technology for continuous biologic production, with similar plants planned in Canada, Brazil, Ireland, France, and Belgium.
Novo Nordisk partners with bluebird on a three-year research arrangement looking to discover gene therapy candidates for the treatment of genetic diseases, including hemophilia.
Merck extends its partnership with 4D Pharma to discover and develop LBP vaccines for three undisclosed indications, adding to their Keytruda partnership.
The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.
Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
HSAC will acquire 100% of the shares of Immunovant, taking the biotech public with $100m in cash and a lead product that set to go through Phase II trials.
Shanghai Pharma and Biocad established a joint venture to commercialize the latter’s portfolio of biosimilars and biologic treatments for the Chinese market.
GSK’s biopharmaceutical manufacturing facility will be focused on the company’s pipeline of biologic medicines, including gene therapies, and vaccines.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
McKesson partners with TrakCel aiming to address the supply chain challenges of cell and gene therapy developers in late stages of development or approaching commercialization.
Four pharma companies are providing half of the investment required for ‘world’s largest genetics project’, in return for access to the genomic data generated.
South Korea looks to accelerate review timelines and study start-up with a new five-year plan that will benefit biotechs looking for locations outside the US to ‘ramp up’ clinical development programs, says CRO.
The seventh #NLSDays event saw the latest trends in fields including ATMP, clinical evolution, and R&D technologies, find their audience in Scandinavia.
Noile-Immune signs its second high profile agreement, the latest with Adaptimmune to combine the companies’ technology in pre-clinical studies for the treatment of cancer.
Already in 2019, there have been a number of deals to pick up vector and plasmid manufacturers, such acquisitions are a sign of a rapidly developing market, one report suggests.
Atelerix to work on the development of gel stabilisation technologies enabling room temperature storage of Rexgenero’s cell therapy candidate, under an Innovate UK grant.
UK government invests further in businesses manufacturing advanced therapies, opening a fund for companies working on technology to improve commercial production.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
